303 related articles for article (PubMed ID: 18501785)
1. C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients.
Schieren G; Tokmak F; Lefringhausen L; van Bracht M; Perings C; Willers R; Günsel A; Kemper F; Wiesmüller GA; Rump LC
Am J Kidney Dis; 2008 Jun; 51(6):976-86. PubMed ID: 18501785
[TBL] [Abstract][Full Text] [Related]
2. Acute phase reaction to gadolinium-DTPA in dialysis patients.
Steen H; Giannitsis E; Sommerer C; Bahner U; Brandl M; Merbach C; Merten C; Ritz E; Katus HA; Zeier M; Schwenger V
Nephrol Dial Transplant; 2009 Apr; 24(4):1274-7. PubMed ID: 19042926
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
[TBL] [Abstract][Full Text] [Related]
4. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
Voth M; Rosenberg M; Breuer J
Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
[TBL] [Abstract][Full Text] [Related]
5. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B
Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
[TBL] [Abstract][Full Text] [Related]
6. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
Abraham JL; Thakral C; Skov L; Rossen K; Marckmann P
Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
[TBL] [Abstract][Full Text] [Related]
7. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents.
Kimura J; Ishiguchi T; Matsuda J; Ohno R; Nakamura A; Kamei S; Ohno K; Kawamura T; Murata K
Radiat Med; 2005 Aug; 23(5):322-6. PubMed ID: 16342903
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance contrast enhancement with gadolinium-DTPA in patients with angina and angiographically normal coronary arteries: effect of chronic beta-blockade.
Rossetti E; Fragasso G; Mellone R; Vanzulli A; Del Maschio A; Chierchia SL
Cardiologia; 1999 Jul; 44(7):653-9. PubMed ID: 10476591
[TBL] [Abstract][Full Text] [Related]
9. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
[TBL] [Abstract][Full Text] [Related]
11. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis.
Marckmann P; Nielsen AH; Sloth JJ
Nephrol Dial Transplant; 2008 Oct; 23(10):3280-2. PubMed ID: 18436563
[TBL] [Abstract][Full Text] [Related]
12. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine.
Shellock FG; Parker JR; Pirovano G; Shen N; Venetianer C; Kirchin MA; Spinazzi A
J Magn Reson Imaging; 2006 Dec; 24(6):1378-85. PubMed ID: 17078095
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of poly(L-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent.
Wen X; Jackson EF; Price RE; Kim EE; Wu Q; Wallace S; Charnsangavej C; Gelovani JG; Li C
Bioconjug Chem; 2004; 15(6):1408-15. PubMed ID: 15546209
[TBL] [Abstract][Full Text] [Related]
14. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
[TBL] [Abstract][Full Text] [Related]
15. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.
Snaedal S; Heimbürger O; Qureshi AR; Danielsson A; Wikström B; Fellström B; Fehrman-Ekholm I; Carrero JJ; Alvestrand A; Stenvinkel P; Bárány P
Am J Kidney Dis; 2009 Jun; 53(6):1024-33. PubMed ID: 19394732
[TBL] [Abstract][Full Text] [Related]
16. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide.
Steger-Hartmann T; Raschke M; Riefke B; Pietsch H; Sieber MA; Walter J
Exp Toxicol Pathol; 2009 Nov; 61(6):537-52. PubMed ID: 19131226
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenic system fibrosis: a radiologist's practical perspective.
Martin DR
Eur J Radiol; 2008 May; 66(2):220-4. PubMed ID: 18321672
[TBL] [Abstract][Full Text] [Related]
18. Risk of acute kidney injury after exposure to gadolinium-based contrast in patients with renal impairment.
Chien CC; Wang HY; Wang JJ; Kan WC; Chien TW; Lin CY; Su SB
Ren Fail; 2011; 33(8):758-64. PubMed ID: 21777176
[TBL] [Abstract][Full Text] [Related]
19. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol.
Zizka J; Klzo L; Ferda J; Mrklovský M; Bukac J
Eur J Radiol; 2007 May; 62(2):186-91. PubMed ID: 17367974
[TBL] [Abstract][Full Text] [Related]
20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
